导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.20% | 1278/4773 |
| 近一周 | -1.02% | 1526/5465 |
| 近一月 | -3.57% | 2639/5421 |
| 近一季 | -8.44% | 3273/5231 |
| 近半年 | -3.99% | 2677/4920 |
| 近一年 | 9.80% | 1162/4394 |
| 近两年 | 79.90% | 849/2954 |
| 近三年 | 42.69% | 701/2253 |
| 成立以来 | 162.43% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.98% 1110/4961 |
19.88% 1271/5312 |
- - |
- - |
| 2025 | 32.70% 1166/4813 |
2.27% 1419/3635 |
1.95% 1997/4076 |
25.80% 1377/4524 |
1.17% 1489/4813 |
| 2024 | 7.43% 1659/3463 |
-2.70% 1412/2808 |
-5.34% 1696/3014 |
16.87% 1327/3129 |
-0.19% 1342/3463 |
| 2023 | -5.97% 798/2656 |
7.95% 510/2280 |
-4.22% 1097/2385 |
-4.63% 1189/2515 |
-4.63% 1121/2655 |
| 2022 | -19.15% 807/2207 |
-14.06% 897/1919 |
2.86% 1245/2016 |
-10.93% 468/2113 |
2.67% 863/2208 |
| 2021 | 17.82% 222/1822 |
-1.35% 475/1255 |
9.95% 509/1330 |
4.78% 319/1466 |
3.67% 405/1822 |
| 2020 | 23.60% 649/1250 |
-3.97% 332/1028 |
17.04% 395/1067 |
6.58% 827/1164 |
3.18% 939/1184 |
| 2019 | 27.51% 542/1092 |
32.98% 154/754 |
-10.05% 712/804 |
0.31% 531/850 |
6.28% 633/918 |
| 2018 | -32.03% 515/834 |
- - |
- - |
- - |
-12.77% 482/691 |
| 2017 | 0.78% 470/714 |
- - |
- - |
- - |
- - |
| 2016 | -16.75% 385/605 |
- - |
- - |
- - |
- - |
| 2015 | 38.78% 48/575 |
- - |
- - |
- - |
- - |
| 2014 | 38.71% 131/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发中证500ETF VS. 长安沪深300非周期A(740101) |